Deals Of The Week: Shire/Pervasis, Takeda/URL, Amgen/KAI
Executive Summary
By adding Pervasis’ endothelial cell technology to the expertise it added with last year’s buyout of Advanced BioHealing, Shire is hoping to build its Regenerative Medicine unit into another powerhouse division, like its Human Genetic Therapies unit.